Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022

Veneti, Lamprini; Berild, Jacob Dag; Watle, Sara Viksmoen; Starrfelt, Jostein; Greve-Isdahl, Margrethe; Langlete, Petter; Bøås, Håkon; Bragstad, Karoline; Hungnes, Olav; Meijerink, Hinta

doi:10.1101/2022.03.24.22272854

Cited by 19 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with evidence on vaccine protection among children and adolescents in other countries. 2,[29][30][31][32][33] This study has limitations. With the lower severity of SARS-CoV-2 infection among children 32,34 and the lower severity of Omicron infections, 35,36 there were too few severe, 12 critical, 12 or fatal 13 COVID-19 cases to estimate vaccine effectiveness against severe forms of COVID-19.…”

Section: Discussionmentioning

confidence: 95%

Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar

Chemaitelly

AlMukdad

Ayoub

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: The BNT162b2 COVID-19 vaccine is authorized for children 5-11 years of age and adolescents 12-17 years of age, but in different dose sizes. We assessed BNT162b2 real-world effectiveness against SARS-CoV-2 infection among children and adolescents in Qatar. Methods: Three matched, retrospective, target-trial, cohort studies were conducted to compare incidence of SARS-CoV-2 infection in the national cohort of vaccinated individuals to incidence in the national cohort of unvaccinated individuals. Associations were estimated using Cox proportional-hazards regression models. Results: Effectiveness of the 10 micrograms dose for children against Omicron infection was 25.7% (95% CI: 10.0-38.6%). It was highest at 49.6% (95% CI: 28.5-64.5%) right after the second dose, but waned rapidly thereafter and was negligible after 3 months. Effectiveness was 46.3% (95% CI: 21.5-63.3%) among those aged 5-7 years and 16.6% (-4.2-33.2%) among those aged 8-11 years. Effectiveness of the 30 micrograms dose for adolescents against Omicron infection was 30.6% (95% CI: 26.9-34.1%), but many adolescents were vaccinated months earlier. Effectiveness waned with time after the second dose. Effectiveness was 35.6% (95% CI: 31.2-39.6%) among those aged 12-14 years and 20.9% (13.8-27.4%) among those aged 15-17 years. Effectiveness of the 30 micrograms dose for adolescents against pre-Omicron infection was 87.6% (95% CI: 84.0-90.4%) and waned relatively slowly after the second dose. Conclusions: Pediatric vaccination is associated with modest and rapidly waning protection against Omicron infection. Adolescent vaccination is associated with stronger and more durable protection, perhaps because of the larger dose size. Age at such young age appears to play a role in determining vaccine protection, with greater protection observed in younger than older children or adolescents.

show abstract

Section: Discussionmentioning

confidence: 95%

Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar

Chemaitelly

AlMukdad

Ayoub

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…VE against Omicron infection peaked at 53% (95%CI: 43-62) at 7-34 days and decreased to 23% (95%CI: 3-40) at ≥63 days post-vaccination. 10 A TND conducted by Powell et al in the UK among 12-15-year-olds, where an extended 8-12-week dosing interval was also used, found two-dose VE against symptomatic infection 7-13 days post-vaccination of 93% (95%CI: 82-98) during Delta and 83% (95%CI: 78-87) during Omicron periods. 11 For 16-17-year-olds, two-dose VE at 14-34 days post-vaccination was 96% (95%CI: 95-97) and 71% (95%CI: 69-73) during Delta and Omicron periods, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…In several postmarketing studies conducted elsewhere among adolescents, mRNA vaccine effectiveness (VE) exceeded 90% against infection and hospitalization during the pre-Omicron period. [5][6][7][8][9][10][11][12][13][14] Fewer studies have assessed adolescent VE post-Omicron emergence, 12 with the United Kingdom (UK) reporting rapid decline against Omicron beginning one month after the second dose. 11,15 Here we report two-dose BNT162b2 VE among adolescents 12-17 years old in Quebec and BC, Canada between September 2021 and April 2022.…”

Section: Introductionmentioning

confidence: 99%

BNT162b2 effectiveness against Delta & Omicron variants in teens by dosing interval and duration

Ionescu

Skowronski

Sauvageau

et al. 2022

Preprint

View full text Add to dashboard Cite

Background and Objectives Two- and three-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccine effectiveness (VE) against SARS-CoV-2 infection, including Delta and Omicron variants, was assessed among adolescents in two Canadian provinces where first and second doses were spaced longer than the manufacturer-specified 3-week interval. Methods Test-negative design estimated VE against laboratory-confirmed SARS-CoV-2 infection among adolescents 12-17 years old in Quebec and British Columbia, Canada between September 5, 2021 (epi-week 36), and April 30, 2022 (epi-week 17). Delta-dominant and Omicron-dominant periods spanned epi-weeks 36-47 and 51-17, respectively. VE was assessed from 14 days and explored by interval between first and second doses, time since second dose, and with administration of a third dose. Results Median first-second dosing-interval was ~8 weeks and second-third dosing-interval was ~28-31 weeks. Median follow-up post-second-dose was ~10-11 weeks for Delta-dominant and ~21-22 weeks for Omicron-dominant periods, and ~3-9 weeks post-third dose. VE against Delta was ≥90% to at least the 5th month post-second dose. VE against Omicron declined from ~65-75% at 2-3 weeks to ≤50% by the 3rd month post-vaccination, restored to ~60-65% shortly following a third dose. VE exceeded 90% against Delta regardless of dosing-interval but appeared improved against Omicron with ≥8 weeks between first and second doses. Conclusion In adolescents, two BNT162b2 doses provided strong and sustained protection against Delta but reduced and rapidly-waning VE against Omicron. Longer interval between first and second doses and a third dose improved Omicron protection. Updated vaccine antigens, increased doses and/or dosing-intervals may be needed to improve adolescent VE against immunological-escape variants.

show abstract

“…For each vaccine type ', we assumed: (i) the first dose provided no protection against infection, i.e. "# !,$ (%) = 0 [27]; (ii) "# !,# (0) depended on the number but not the time of previous doses; (iii) VE waned exponentially at rate -! after each dose [5,28,29], i.e.…”

Section: Statistical Inference Of Vementioning

confidence: 99%

Population-based sero-epidemiological estimates of real-world vaccine effectiveness against Omicron infection in an infection-naive population, Hong Kong, January to July 2022

Lau

Cheng

Leung

et al. 2022

Preprint

View full text Add to dashboard Cite

The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and escape of vaccine-derived immunity. While current vaccines remain effective against severe disease and death, robust evidence on vaccine effectiveness (VE) against all Omicron infections (i.e. irrespective of symptoms) remains sparse. We addressed this knowledge-gap using a community-wide serosurvey with 5,310 subjects by estimating how vaccination histories modulated risk of infection in Hong Kong (which was largely infection naive) during a large wave of Omicron epidemic during January-July 2022. We estimated that Omicron infected 45% (41-48%) of the Hong Kong population. Three and four doses of BNT162b2 or CoronaVac were effective against Omicron infection (VE of 47% (95% credible interval 34-68%) and 70% (43-99%) for three and four doses of BNT162b2 respectively; VE of 31% (1-73%) and 59% (10-99%) for three and four doses of CoronaVac respectively) seven days after vaccination, but protection waned with half-lives of 15 (3-47) weeks for BNT162b2 and 5 (1-37) weeks for CoronaVac. Our findings suggest that booster vaccination can temporarily enhance population immunity ahead of anticipated waves of infections.

show abstract

Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022

Cited by 19 publications

References 18 publications

Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar

Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar

BNT162b2 effectiveness against Delta & Omicron variants in teens by dosing interval and duration

Population-based sero-epidemiological estimates of real-world vaccine effectiveness against Omicron infection in an infection-naive population, Hong Kong, January to July 2022

Contact Info

Product

Resources

About